189 related articles for article (PubMed ID: 16934317)
1. The prognostic significance of thrombocytosis in uterine papillary serous carcinomas.
Lerner DL; Walsh CS; Cass I; Karlan BY; Li AJ
Gynecol Oncol; 2007 Jan; 104(1):91-4. PubMed ID: 16934317
[TBL] [Abstract][Full Text] [Related]
2. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma.
Bristow RE; Duska LR; Montz FJ
Gynecol Oncol; 2001 Apr; 81(1):92-9. PubMed ID: 11277657
[TBL] [Abstract][Full Text] [Related]
3. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.
Thomas MB; Mariani A; Cliby WA; Keeney GL; Podratz KC; Dowdy SC
Gynecol Oncol; 2007 Nov; 107(2):190-3. PubMed ID: 17825394
[TBL] [Abstract][Full Text] [Related]
4. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma.
Olawaiye AB; Rauh-Hain JA; Withiam-Leitch M; Rueda B; Goodman A; del Carmen MG
Gynecol Oncol; 2008 Sep; 110(3):293-8. PubMed ID: 18644620
[TBL] [Abstract][Full Text] [Related]
5. Preoperative thrombocytosis predicts poor survival in patients with glioblastoma.
Brockmann MA; Giese A; Mueller K; Kaba FJ; Lohr F; Weiss C; Gottschalk S; Nolte I; Leppert J; Tuettenberg J; Groden C
Neuro Oncol; 2007 Jul; 9(3):335-42. PubMed ID: 17504931
[TBL] [Abstract][Full Text] [Related]
6. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
Kelly MG; O'malley DM; Hui P; McAlpine J; Yu H; Rutherford TJ; Azodi M; Schwartz PE
Gynecol Oncol; 2005 Sep; 98(3):353-9. PubMed ID: 16005947
[TBL] [Abstract][Full Text] [Related]
7. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma.
Hamilton CA; Cheung MK; Osann K; Balzer B; Berman ML; Husain A; Teng NN; Kapp DS; Chan JK
Gynecol Oncol; 2006 Nov; 103(2):679-83. PubMed ID: 16793126
[TBL] [Abstract][Full Text] [Related]
8. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma.
Rauh-Hain JA; Growdon WB; Schorge JO; Goodman AK; Boruta DM; McCann C; Horowitz NS; del Carmen MG
Gynecol Oncol; 2010 Nov; 119(2):299-304. PubMed ID: 20691465
[TBL] [Abstract][Full Text] [Related]
9. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
Goldberg H; Miller RC; Abdah-Bortnyak R; Steiner M; Yildiz F; Meirovitz A; Villà S; Poortmans PM; Azria D; Zidan J; Ozsahin M; Abacioglu U; Gold DG; Amit A; Lavie O; Atahan IL; Kuten A;
Gynecol Oncol; 2008 Feb; 108(2):298-305. PubMed ID: 18096209
[TBL] [Abstract][Full Text] [Related]
10. Thrombocytosis in advanced epithelial ovarian cancer.
Soonthornthum T; Suraseraneewong V; Kengsakol K; Wijaithum K; Kasemsan P; Prommatt S
J Med Assoc Thai; 2007 Aug; 90(8):1495-500. PubMed ID: 17926975
[TBL] [Abstract][Full Text] [Related]
11. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
Kelly MG; O'Malley D; Hui P; McAlpine J; Dziura J; Rutherford TJ; Azodi M; Chambers SK; Schwartz PE
Gynecol Oncol; 2004 Dec; 95(3):469-73. PubMed ID: 15581948
[TBL] [Abstract][Full Text] [Related]
12. p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma.
Bancher-Todesca D; Gitsch G; Williams KE; Kohlberger P; Neunteufel W; Obermair A; Heinze G; Breitenecker G; Hacker NF
Gynecol Oncol; 1998 Oct; 71(1):59-63. PubMed ID: 9784320
[TBL] [Abstract][Full Text] [Related]
13. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
[TBL] [Abstract][Full Text] [Related]
14. Androgen mediation of thrombocytosis in epithelial ovarian cancer biology.
Li AJ; Karlan BY
Clin Cancer Res; 2005 Nov; 11(22):8015-8. PubMed ID: 16299230
[TBL] [Abstract][Full Text] [Related]
15. Uterine papillary serous carcinoma: patterns of failure and survival.
Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V
Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700
[TBL] [Abstract][Full Text] [Related]
16. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).
Fields AL; Einstein MH; Novetsky AP; Gebb J; Goldberg GL
Gynecol Oncol; 2008 Jan; 108(1):201-6. PubMed ID: 17997145
[TBL] [Abstract][Full Text] [Related]
17. Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma.
Schmidt M; Segev Y; Sadeh R; Suzan E; Feferkorn I; Kaldawy A; Kligun G; Lavie O
Int J Gynecol Cancer; 2018 Sep; 28(7):1311-1317. PubMed ID: 29958235
[TBL] [Abstract][Full Text] [Related]
18. [Uterine papillary serous carcinoma and papillary endometrial carcinoma: analysis of clinical biological behaviors of 56 cases].
Sun X; Shi S; Sheng X
Zhonghua Fu Chan Ke Za Zhi; 1996 Jan; 31(1):8-11. PubMed ID: 8758810
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of hematological parameters in women with uterine serous papillary carcinoma (USPC).
Younes G; Segev Y; Begal J; Auslender R; Goldberg Y; Amit A; Lavie O
Eur J Obstet Gynecol Reprod Biol; 2016 Apr; 199():16-20. PubMed ID: 26894377
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma.
Sagr ER; Denschlag D; Kerim-Dikeni A; Stanimir G; Gitsch G; Gilbert L
Anticancer Res; 2007; 27(2):1213-7. PubMed ID: 17465265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
